Medidata Expands Partnership with BeiGene to use Medidata’s Patient Cloud ePRO Solution
July 24 2017 - 5:30PM
Business Wire
Expanded Partnership Includes Medidata Patient
Cloud ePRO to Seamlessly Collect Patient-Centric Data and Automate
Manual Processes for Oncology Research
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced that BeiGene, Ltd., a clinical-stage
biopharmaceutical company developing innovative molecularly
targeted and immuno-oncology drugs for the treatment of cancer,
will expand its use of the Medidata Clinical Cloud® to further
digitize patient reporting for its oncology research studies.
BeiGene will leverage Medidata’s integrated platform to feed
eSource Patient Reported Outcome data from Medidata’s Patient Cloud
ePRO directly into Medidata Rave®. This infusion of patient
recorded outcome data will enable improved operational efficiency,
reduced transcription errors and reconciliation issues, and
decreased data quality risk plans.
“Our expanded partnership with Medidata will establish a
technology platform for our clinical research, which we expect will
enable us to more efficiently execute clinical trials of our
portfolio compounds,” said Ross Pettit, Senior Vice President of
Global Development Operations at BeiGene. “Over the past two years,
Medidata has proven to be a key technology partner for BeiGene,
with its industry-leading solutions and hands-on approach to our
integration needs. By automating paper-based procedures and
centralizing patient data on the Medidata platform, we’re able to
collaborate globally on our oncology research.”
As part of its expanded partnership with Medidata, BeiGene also
plans to standardize the collection and management of safety cases
through Medidata Safety Gateway®, a secure, configurable electronic
transmission interface between EDC and safety systems. The
partnership between BeiGene and Medidata also includes Medidata
Coder®, a cloud application that is designed to streamline and
centralize medical coding to perform oncology research studies.
“Medidata is proud to be accelerating technology advancement at
every level and interaction within the life sciences industry,”
said Kara Dennis, Managing Director of Mobile Health at Medidata.
“We’ve created an environment that is agile, globally
collaborative, and in line with the digital and mobile needs of
biotechnology and pharmaceutical companies, all from one unified
cloud platform. BeiGene’s forward-thinking technology approach will
enable faster study builds and centralized control over patient
data, facilitating the evaluation of its portfolio compounds.”
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
About BeiGene
BeiGene is a global, clinical-stage, research-based
biotechnology company focused on molecularly targeted and
immuno-oncology cancer therapeutics. With a team of over 400
employees in China, the United States, and Australia, BeiGene is
advancing a pipeline consisting of novel oral small molecules and
monoclonal antibodies for the treatment of cancer. BeiGene is
working to create combination solutions aimed at having both a
meaningful and lasting impact on cancer patients.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170724006244/en/
Medidata SolutionsInvestors:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2023 to Sep 2024